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Prediction of kidney mercury content by isotope techniques. A 61-year-
old female patient accidentally aspirated liquid mercury during a
medically ordered diagnostic procedure. To develop animal-based
guidelines, liquid mercury was introduced into the lungs of four dogs.
Based on the study of these animals, a method of predicting the kidney
inorganic mercury burden was developed using radioactive isotope
dilution techniques. It was further demonstrated in dogs that oral
administration of dimercaptopropane sulfonate (DMPS) increased mer-
cury excretion and reduced the kidney burden, A rat experiment was
performed permitting a statistical evaluation of the assumptions basic to
the use of the method. The method was applied to the patient with the
result that the kidney inorganic mercury burden was predicted to be
28.1 mg, 8 months after the accident. Treatment with DMPS increased
urinary excretion and the post-treatment kidney burden was estimated
at 19.6 mg Hg. Inasmuch as the radioactive dose to the subject may be
kept at a negligible level and because sensitive methods exist for
measurement of radioactive and stable mercury concentrations, the
technique may be applicable in special cases to the estimation of kidney
inorganic mercury burdens incurred by industrial exposure.
Prediction du contenu renal en mercure par des techniques isotopiques.
Une femme de 61 ans a aspire accidentellement du mercure liquide
pendant un acte diagnostique prescrit par un médecin. Afin de
developper des bases d'origine animale, du mercure liquide a été
introduit dans les poumons de quatre chiens. D'après l'étude des ces
animaux, une mdthode permettant de prévoir le contenu renal en
mercure inorganique a été développée par des techniques de dilution
d'isotope radioactif. Ii a ensuite ete montré chez des chiens que
l'administration orale de sulfonate de dimercaptopropane (DMPS)
augmentait l'excrétion mercurielle et en réduisait le contenu renal. Une
experience a été entreprise chez le rat pour permettre une evaluation
statistique des hypotheses de base permettant l'emploi de la méthode.
Cette méthode a été appliquee a malade, et a permis de prddire que le
contenu renal en mercure inorganique était de 28,1 mg, 8 mois apres
l'accident. Le traitement au DMPS a augmente l'excrétion urinaire et le
contenu renal post-therapeutique a été estimé a 19,6 mg Hg. Dans Ia
mesure oi la dose radioactive donnée au sujet peut étre maintenue a un
niveau négligeable, et puisqu'il existe des méthodes sensibles de
mesure des concentrations de mercure radioactif et stable, cette tech-
nique est applicable a des cas particuliers pour estimer le contenu renal
en mercure inorganique lie It une exposition industrielle.
Scientific reviews [1] and reports from investigative groups
[2] agree that measurements of mercury in urine, blood, hair,
and other indicator media do not in themselves yield a reliable
estimate of the body mercury burden or, more specifically, the
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kidney mercury burden. The kidney burden assumes particular
importance because the kidney is the principal organ of ac
cumulation and one of the main targets for toxic effects of
inorganic mercury. Chisolm [3] has proposed the use of
complexing agents to estimate the body's burden of lead in
children. This procedure has now become a standardized
protocol in which a dose of calcium EDTA is injected and 24-hr
urine collections are made before and after the treatment.
However, no comparable procedure has been tested for mer-
cury determination.
The opportunity to explore the use of a radioactive mercury
isotope to estimate the kidney burden of non-radioactive mer-
cury occurred when a 61-year-old woman ruptured a liquid
mercury-containing bag by coughing as the intestinal tube was
being passed down her throat, with the result that she aspirated
a substantial fraction of the mercury released. The attending
physician turned her upside down and shook her vigorously but
failed to dislodge the bulk of the material which had rapidly
penetrated to the small airways. The clinical course of the
patient and the special studies performed will be described in
other communications. Suffice it to say that the patient re-
mained symptom-free for a period of 6 months and only at the
end of that time developed a mild proteinuria. The consensus of
medical opinion was that it would be valuable to determine the
kidney burden of mercury and, if possible, to reduce it by
chelation therapy.
In anticipation of the need for animal-based guidelines,
studies were made on four dogs with experimentally produced
lung burdens of liquid mercury. Because it seemed likely that
the kidney would he the vulnerable organ, we explored means
of estimating the accumulation of mercury at that site by means
of isotope dilution techniques. The data showed that (1) the
kidney mercury burden could be inferred by assuming that 30%
of an intravenous dose of radioactive mercury (203Hg;
nonradioactive mercury is represented by jxg Hg) was taken up
by the dog kidney and that the specific activity of the kidney
(MCi 203Hg/g Hg) was equal to the specific activity of the urine
and (2) that the amount of kidney mercury burden reduction
brought about by chelation therapy could be estimated by a
subsequent 203Hg dose.
These isotope techniques were applied to the patient, and it
was found that the kidney burden was reduced from 28.1 mg Hg
to 19.6 following an oral course of treatment with dimercapto-
propane sulfonate (DMPS).
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To extend the supportive evidence to another animal species,
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Fig. 1. Reproduced from x-ray films of dog 3
taken at times as shown after insufflalion of 7.4 g
liquid mercury. Some of the small mercury
spheres have been enhanced to increase the
contrast.
increase the number of animals, and to further investigate the
effect of DMPS on the assumptions underlying this application
of the isotope dilution technique a rat experiment was added.
The details of the dog experiment, the additional rat data, and
the application of method to the patient during a period from
231 to day 249 after insufflation will be presented in this paper.
Methods: Dogs
Procedure. A bronchoscope was used to introduce 7 to 15 g
of liquid mercury into the lungs of lightly anesthetized adult
dogs. The location in the lungs and the subsequent shifts in
position and degree of subdivision were followed by chest
roentgenograms. Figure 1 shows a typical set of changes with
time.
All dogs were housed in metabolism cages. Preinsufflation
blood and urine samples were collected and analyzed for
mercury. Food samples were analyzed and shown to have
negligible mercury content. Creatinine clearances were per-
formed to verify normal kidney function.
After liquid mercury was introduced, daily blood samples and
24-hr urine collections were begun. Hematocrit was measured;
whole blood, plasma, and urine were analyzed for the
nonradioactive inorganic mercury (Hg) concentration. Three of
the four dogs received an intravenous dose of 203Hg, the 46.6
day hall-life isotope of mercury. The 203Hg was supplied by the
New England Nuclear Corp., Boston, Massachusetts, USA.
The dose was injected as HgCl2 in a volume of less than or equal
to S ml isotonic saline solution; the specific activity varied from
0.60 to 3.0 Ci/sg. Size of dose, interval before dosing, and
other items pertaining to the dogs appear in Table 1. Following
the dose of 203Hg, radioactivity measurements were made on
the blood and urine samples. After 3 (dog 2) or 5 (dogs 3 and 4)
days following the 203Hg injection, the animals were sacrificed
and tissue samples were selected for stable (Hg) and radioactive
(203Hg) mercury determinations. Because the experimental plan
called for a comparison between a control dog and a DMPS-
treated dog, these two dogs were pure-bred adult beagles
39 days7 days
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Table 1. Data on four dogs who received intrapulmonary liquid
mercury
300
Weight, kg
Sex
Hg, g
Study period, days
DMPS, 4
mg/kg/day
Dog! Dog2 Dog3
27 8 9
M F F
15 8.0 7.4
14 11 41
a The specific activity was in the range of 0.60 to 3.04 sCi/g.
matched for age, weight, and sex. The other two dogs were of
uncertain antecedents.
DMPS was administered to dog 4 by mouth at the rate of 4 mg
(19 mo1es) per kg per day for 8 days. Radiation measurements
of small volume liquid samples were made in the auto-gamma
spectrometer (Packard Instrument Co., Downer's Grove, Il-
linois, USA) with a Nal (Ti) crystal detector. Larger volume
samples were counted in the liquid scintillation counter
(Armac, Packard Instrument Co.). Inorganic mercury (Hg) was
measured by cold vapor atomic absorption [4, 5]. The mercury
vapor contained in large volume gas samples (that is, 12-liter
bags of expired air collected from the patient) was adsorbed or
silver wool [6], then released by heating and passed with a small
puff of air into the atomic absorption unit. The sensitivity of this
method is 0.9 ng Hg. Tissue samples were homogenized and
digested with NaOH, reduced by a modified method [71 of
Clarkson and Greenwood [8]. The mercury vapor was swept
into the atomic absorption spectrometer. The precision of the
method is 8.7% relative standard deviation (rsd).
Results: Dogs
In addition to the routine measurements conducted on all
dogs, noted above, some special studies were performed on
single dogs. Two days after mercury-insufflation, dog 1 under-
went ventilation-perfusion scintigraphy tests for impaired lung
function [9, 10]. These tests were negative, agreeing with
patient findings [11, 12], which confirm the absence of chronic
respiratory complications following accidental inhalation of
mercury.
Figure 1 shows a series of anterior-posterior chest x-rays on
dog 3 beginning immediately after insufflation followed by films
taken on days 4, 7, and 39. The initial deposit is shown filling a
portion of the bronchiolar network of the left lung. By day 4, the
formerly consolidated mercury has been dispersed into multiple
small spheres. This dispersal probably is achieved quite
promptly; the series on dog 1 (not illustrated in the figure)
includes a film taken 1 day after insufflation showing that
complete dispersal had occurred already. The x-ray sequence
on the patient (as illustrated in another communication) shows
a marked resemblance to the dog x-ray series.
Coincident with the dispersal, a fraction of the deposit is
coughed up or moved up by the lung cilia, swallowed, and
appears in the gastrointestinal tract. This may be noted in the
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7-day film (Fig. 1) as a collection of mercury spheres conform-
ing to the outline of the large intestine. The fraction which is
removed from the dog's lungs by this means has not been
determined and may vary from dog to dog.
It is of further interest to note that once established, the
pattern of location in the lung of the small mercury spheres
remains unaltered from days 4 to 39. This is probably caused by
the early formation of firm yellowish lung nodules containing
the mercury droplets as noted by Conrad, Sandford, and
Preston [13] and by us at necropsy. They are mentioned at this
point to explain the unchanging pattern and to support the
proposal that after nodule formation, removal of mercury from
the lung occurs only by vapor evolution and solution in the
blood or by in situ oxidation of mercury and its subsequent
removal as mercuric ions in the circulating blood.
Mercury content of the blood. Figure 2 shows the mercury
content of the red blood cells and the plasma for each of the four
dogs. Mercury concentrations are expressed without normal-
izing in terms of the amounts of insufflated liquid mercury
because the rate of mobilization of inorganic ions from these
deposits is believed to depend not only on the size of the
insuffiated lung burden but also on unevaluated factors such as
the surface-to-mass ratio of the deposit and the level of exercise
displayed by the subject, to say nothing of the unmeasured loss
by swallowing. Despite the irregularity of the day-to-day vari-
ations in the same dog and the difference from dog to dog, two
generalizations can be formed from these data: (1) that the
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Fig. 2. Concentration qf mercury in the plasma and red blood cells of
four dogs as a function qf time after insufflation. Symbols are: , dog
1; i, dog 2; 0, dog 3; 0, dog 4.
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Time, days after insufflation
Fig. 3. Daily mercury excretion in the urine of four dogs as a function
of time after insufflation.
concentration of mercury in the red blood cells is higher than
that in the plasma, particularly in the first 10 days and, (2) that
the treatment of dog 4 with DMPS does not produce changes in
blood mercury concentrations.
Mercury content of the urine. Figure 3 shows mercury
excreted per day in the urine. All dogs showed some initial
increase in daily excretion, but this trend appears to be more
pronounced in dogs 1, 2, and 3. During this time, it is probable
that the process of dispersal followed by nodule formation
occurs in the lungs. The difference in the early pattern between
dogs 3 and 4 has no adequate explanation. If the 3-sample peak
of dog 3 is regarded as indicative of the expected early increase,
the lack of this increase in dog 4 remains to be substantiated, It
may be noted (Fig. 2) that the increased urinary excretion of
mercury because of DMPS treatment (dog 4) is not accompa-
nied by a coincident increase in plasma mercury concentration.
Mercury in blood and body organs after intravenous 203Hg.
Table 2 lists the doses in microcuries of 203Hg for injected dogs
2, 3, and 4 as well as the blood, urine and tissue concentrations
of radioactive and stable mercury. The third column lists
specific activity (nCi 203Hg x 103/ng Hg). For our purposes the
most important feature of the table is the demonstrated equality
of the specific activity of the urine and the kidney in the same
dog. The table facilitates a comparison between dogs 2 and 3
sacrificed 11 and 41 days post-insuffiation. The effect of this
increased exposure time is to produce an increase in the
mercury stored in the brain with little or no change in kidney
and liver concentrations. Dogs 3 and 4, sacrificed after the same
time interval, illustrate the effect of oral DMPS treatment. The
treated dog 4 shows a decrease in the mercury burden of the
kidney and of the brain' and a probably significant reduction in
the mercury burden of the heart. The specific activities reflect
these changes in stable mercury storage. It may be noted that
the increase in specific activity of the DMPS dog as compared
to the control dog kidney is not reflected by a corresponding
increase in specific activity of the plasma. No special impor-
tance should be attached to the equality of specific activity of
the urine (or kidney) of dogs 2 and 3 because the intravenous
dose of 203Hg was 5.66 Ci as compared to 4.17 Ci and the
time for mobilization of Hg from the lung deposit was 11 as
compared to 41 days.
Comparison of predicted and measured kidney mercury
burden. Table 3 assembles the pertinent results and lists the
measured and predicted mercury burdens in the kidneys for the
three isotope-injected dogs. The accuracy of the prediction
depends on the validity of the two basic assumptions: (1) that
30% of the injected dose of 203Hg is taken up by the kidney and
(2) that the specific activity of the kidney is equal to the specific
activity of the urine. It will be seen from the table that the
measured values of 203Hg in the kidney of dogs 2, 3, and 4 is
lower than 30% by 5.4, 0.9, and 2.8% units.The ratio of the
specific activity of the kidney to the specific activity of the urine
may be calculated readily from values listed in Table 2 as 0.97,
0.95, and 1.05, respectively, for dogs 2, 3, and 4. These small
departures from unity indicate that the specific activities of the
kidney and urine are equal within expected analytical error.
The mercury burden is predicted by multiplying the intra-
venous 203Hg dose by 0.3 and dividing by the specific activity of
the urine, as shown by the example for dog 2:
(0.3 X 5.66)11.38 x l0 = 1230 g Hg°
= 1.23 mg Hg°
Consequently, the predicted kidney burden (dog 2) is errone-
ously high because in fact, 24.6% of the dose was taken up by
the kidney rather than the assumed 30% (an effect slightly
reduced because the divisor, that is, the specific activity, is
estimated marginally higher than the measured kidney specific
activity). The last line in the table lists the errors of the
predicted burdens as the percent of the measured burden.
Methods: Rats
Procedure. The rat experiment was designed to evaluate the
assumptions (1) that an intravenous dose of 203Hg given to rats
with a pre-existing burden of inorganic Hg will show equality
between the specific activity of the day 3 urine and the kidney;
(2) that at sacrifice on day 3 the kidney will contain 30% of the
203Hg dose, and (3) that treatment with DMPS does not alter
these relationships. Accordingly, all rats received a tail vein
injection of 100 g Hg as HgCl2 in saline to establish a Hg
burden. Ten rats were assigned to a control group and 10 to an
experimental group. Beginning 6 days after Hg injection and
continuing through day 10 rats in the experimental group were
This reduction in brain Hg content brought about by DMPS is
particularly noteworthy in view of the caveat expressed in the report by
international investigators [2] to the effect that BAL is contraindicated
in poisoning by methytmercury because it leads to increased brain
mercury levels.
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Table 2. Body fluids and tissue concentration of Hg and 203Hg at necropsy
Dog 2 (5.66)a Dog 3 (4.17)a Dog 4 (4.27)a
nCi 203Hg ng Hg nCi203Hg x iO nCi 203Hg ng Hg nCi 203Hg x i0 nCi 203Hg ng Hg nCi 203Hg X iO
Fluid or tissue g g ng Hg g g ngHg g g ng Hg
Blood 0.108 46 2.34 0.141 19 7.42 0.108 24 4.5
Plasma 0.142 51 2.78 0.139 24 5.79 0.113 29 3.9
Urine' 0.234 170 1.38 0.091 64 1.42 0.250 100 2.50
Kidney 30.4 22630 1.34 25.5 18900 1.35 21.0 8000 2.63
Liver 1.62 1640 0.988 2.08 2000 1.04 1.81 1800 1.01
Brain 0.0204 72 0.283 0.0365 250 0.146 0.035 80 0.44
Lung 0.379 — — 0.430 — — 0.294 — —
Heart 0.091 — — 0.097 590 0,164 0.098 330 0.296
a The dose is in Ci 203Hg.
b Concentration values are expressed per milliliter and taken from the 24-hr collection just prior to necropsy.
Table 3. Comparison of measured and predicted mercury burdens
Dog2 Dog3 Dog4
% 203Hg dose
2 kidneys
24.6 29.1 27.2
Meas Hg, mg
2 kidneys
1.04 0.92 0.44
Pred Hg, mga 1.23 0.88 0.51
%Error +18 —4 +16
a Predicted Hg burden, assuming 30% of the 203Hg dose goes to the
kidney and assigns a specific activity to the kidney equal to the
measured specific activity of the urine.
given a daily intraperitoneal injection of 3 mg DMPS per kg. On
day 12 all rats received a tail vein injection of 200 nCi 203Hg as
HgC12 in saline. Prompt whole-rat counting in the scintillation
counter yielded individual rat doses which averaged 225 4 nCi
203Hg. The error is the standard error of the mean (sEM). Unless
otherwise specified, where errors are associated with averages
in the tables or text, they are in all cases SEM. After receiving
203Hg the rats were placed in individual metabolic cages. Daily
collection of urine was made for the next 3-day period at the end
of which all rats were sacrificed. Both kidneys, the liver, and
the brain of each animal were weighed and analyzed for 203Hg
and for Hg using the equipment and methods described for the
dog experiment.
Results: Rats
Comparison of specific activities. Table 4 lists the average
concentrations of 203Hg and Hg from the third day urine
collection and for the kidney, liver, and brain. Specific activities
have been calculated for individual rat urine specimens and
organs and the average of these values with the associated SEM
is listed. The difference between the average specific activity of
the urine and the kidney of the control rats is not statistically
significant (0.64 x l0 0.40 x 10). Likewise, the cor-
responding difference for the DMPS-treated rats is not signifi-
cant (0.53 X iO 0.50 X lO—).
Effect of DMPS treatment on Hg content. The average
kidney burden of Hg for the DMPS-treated group is 8.44% of
the injected dose at sacrifice as compared to 11.48% for the
control group; this difference is significant (3.04% 0.61).
Inasmuch as the treatment is expected to reduce Hg in the
kidney, this result testified that the treatment was effective.
However, there is no such significant difference observed in the
liver and brain intergroup comparison: The liver burden differ-
ence equaled 0.23% 0.21%, and the brain burden difference
equaled 0.010% 0.006%.
Effect of DMPS on 203 Hg content. Because of the very rapid
clearance of DMPS from the body (Gabard [141 found in rats
that the half-life equals 19 mm) and because of the 2-day
interval between the last DMPS dose and the 203Hg injection, it
was expected that the DMPS treatment would have no effect on
203Hg distribution in the rat. The percent of the injected dose
per organ was calculated using the measured 203Hg concentra-
tions, the total organ weight, and the post injection whole-rat
count (see Procedure). The resulting average 203Hg kidney
content at necropsy is listed in Table 4 with other similar values
and is found to be 31% 1.1% for the control rats and 30%
1.2% for the DMPS-treated rats. This comparison shows the
absence of any DMPS effect and also that the rat data support
the choice of 30% dose for the postulated kidney uptake. The
average 203Hg content of the liver is 6.23% dose (treated) and
5.90% dose (controls) and the average brain content is 0.097%
dose (treated) and 0.085% dose (controls). These small differ-
ences (liver: 0.33% 0.54% and brain: 0.012% 0.0061%) are
not regarded as statistically significant.
Predicted versus measured kidney burdens. Like the dog data
(in Table 3), the rat data permit a comparison of a predicted
kidney Hg burden using the familiar assumptions with the Hg
burden as actually measured. This was done for each of the 20
rats. The predicted values divided by the measured burdens
yield numbers from 0.79 to 1.32 with an average equaling 1.09
0.03. As was the case for the dog data, the average predicted
value was slightly higher than the measured value.
Methods: Human
Procedure. The procedure with the patient, as with the dogs
and rats, involved an intravenous injection of a radioactive
mercury isotope, oral DMPS administration (300 mg/day for 6
days), and an analysis of whole blood, plasma, and urine for
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Table 4. Average concentration of 203Hg and Hg in rat urine and tissues and specific activities with associated standard error of the mean
Control rats (l0) DMPS-treated rats (l0)
nCi 203Hg ng Hg nCi 203Hg xlO3nCi 203Hg ngHg nCi 203Hgx io
Tissue or fluid g g ng Hg g g ng Hg
Urineb 0.172 30.24 5.72± 0.21 0.219 31.82 7.29 0.50
Kidneys 30.15 4843 6.36 0.34 25.91 3365 7.82 0.31
Liver 1.85 201 10.17 0.96 1.99 246 8.52 0.99
Brain 0.111 31.5 3.32 0.28 0.119 37.9 3.75 0.25
a The number in parentheses represents the number of rats per group.
b Urine was collected for the interval from 48 to 72 hr post 203Hg injection.
both stable and radioactive inorganic mercury. There were,
however, important modifications and additions in the proce-
dure.
To keep the radiation exposure as low as possible, '97Hg with
a half-life of 64.1 hr, was substituted for the 46.6 day half-life
203Hg. The dose was planned to be about 1 Ci rather than the
projected 5 pCi used for dogs. The radiation dose of the
patient's kidney was calculated to be 16 millirads per
microcurie of '97Hg. This dose may be compared to a permis-
sible occupational limit of 300 millirads per week for a 50 year
working lifetime. The radiation doses to organs other than the
kidney are lower by at least an order of magnitude. For the dose
calculation, the general formulae, weights, absorbed dose con-
stants, absorbed fractions, and so forth, were taken from MIRD
publications [15]. The injection dose (in 0.5 to 0.85 ml isotonic
saline with sp act of 0.1 to 2.9 p.Ci per g) was tested for
pyrogens and made sterile by the Pharmacy Department of
Strong Memorial Hospital. Permission to perform the study was
sought and obtained from our hospital committees: the Com-
mittee on Investigations Involving Human Subjects and the
Human Use of Radioisotopes Committee.
The patient was admitted to the Clinical Research Center at
Strong Memorial Hospital, a unit which provided, in addition to
other services, reliable timing and collection of the required
urine and blood samples, Two intravenous doses of 197Hg were
administered; one before and one after DMPS treatment. Be-
fore the isotope was administered and 24 hr after the injection of
each dose, the patient was measured in a whole body counter.
A description of this low background facility which is used to
measure gamma radiation from human subjects may be found in
the International Atomic Energy Agency's Directory of Whole
Body Radioactive Monitors [16]. Measurements were made in
three different Nal (Tl) crystal detector to patient positions.
The "chair" position is described precisely in the reference; it
involves placing the detector in the right angle formed by the
upper legs and trunk while the patient sits in a tilted-back metal
chair. The "kidney" position puts the patient prone on a
wooden platform with the crystal positioning in close ap-
proximation to the body surface and above the kidneys. For the
head position, the patient is supine on the platform and the
crystal detector is just above and touching the side of the head,
a vertical sheet of one-quarter inch thick lead with a neck
cut-out acts to partially shield the detector from 197Hg deposited
elsewhere in the body.
Throughout the experimental period, 12-liter samples of
expired air were collected from the patient. It had been discov-
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ered earlier [17, 18] that human volunteers exposed to a 20-mm
inhalation of mercury vapor continued to expire mercury vapor
for times as long as 3 days. The collection and measurement of
the patient's expired air was intended to explore this possibility
when mercury was constantly released from a liquid mercury
lung store.
Results: Human
Figure 4 shows the 24-hr urinary excretion, the expired air
bag results, and the plasma and red blood cell mercury concen-
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Fig. 4. For the 230 to 250 day period after accidental insufflation, the
mercury concentration in the plasma and red blood cells of the subject,
the concentration of mercury vapor in the expired air, and the daily
mercury urinary excretion.
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Table 5. Measurements of gamma activity before and after intravenous '97Hg injection as registered by the whole body counter for three
different detector-patient positions as described in the text
Before 197Hg
After 1St dose
After 2nd dose
% Difference
Kidney
Net cpma Net cpma Net cpma
Total counts cpm rCi dose Total counts cpm Ci dose Total counts cpm pCi dose
1209 121 — 1318 132 — 995 96 —
87781 8778 16533 140192 28038 53377 13198 1320 2326
204980 20498 17390 292066 58413 49558 30581 3058 2530
+5.2 —7.2 +8.8
a The net counts per minute have been corrected for loss by radioactive decay from the time the dose was given and normalized to I pCi dose.
For the second dose, an additional correction is made for activity remaining from the first dose with effective half-times taken from [14].
Inj dose Spec act urinea Predicted
Kidney 97Hg Hg kidney
'97Hg Hg burden pCjb >< iO burden
Cjb p.g pCjb /Lg mg
Before DMPS 0.693 0.23 0.208 0.74 28.1
After DMPS 1.53 7.1 0.459 2.34 19.6
tration for the 230 to 250 day post-exposure experimental
period. The increase in urinary excretion caused by DMPS is
clearly evident as well as the sharp drop when the treatment is
stopped. The mercury vapor in the expired air varies somewhat
from day to day but does not appear to be affected by DMPS
and shows no consistent trend with time, Samples collected
during the period from 5 to 15 days postinsufflation (not shown
in Fig. 4) fall in the same range of mercury vapor concentration.
The plasma concentration seems likewise unaffected, the
20% drop in mercury level occurring between days 234 and 235
was measured in a blood sample drawn just prior to the
beginning administration of DMPS and is therefore not perti-
nent. As illustrated in Figure 4, the mercury concentration in
red cells is always less than the concentration in plasma. The
related concentration ratio averaged 0.63 0.03 SEM.
Table 5 lists the results of the whole body counter gamma
activity measurements of the patient. The values of net
cpm//LCi in the third column should be the same for the first and
second dose if three conditions are fulfilled: (1) that the injected
197Hg doses as stipulated (see Table 6) are relatively correct, (2)
that the detector to patient geometry has been faithfully re-
produced, and (3) that the prompt body distribution of '97Hg is
not affected by the reduced burden of Hg in the kidney and
other organs brought about by DMPS. The fact that the
cpm/tCi are almost the same for a given position and that the
differences as shown in the table do not exceed 9% supplies an
assurance that the conditions are fulfilled.
Table 6 lists the estimated kidney burden of mercury before
and after treatment with DMPS; the burdens are calculated in
the same way as done for the dogs and rats. According to these
estimates, 8.7 mg or 31% of the burden has been removed by
the 6-day treatment. It may perhaps be noted that the absolute
value of the specific activity of the urine is important only
inasmuch as it identifies the specific activity of the kidney and
that this identity is independent of the dose of 197Hg adminis-
tered. Table 6 specifies the small amount of Hg that is injected
with the 19711g dose to show that these amounts are insignificant
in comparison with the already present Hg mobilized from the
lung,
Discussion
Reliability of the kidney burden estimate. The precision of the
197Hg dose measurement and the measurement of the urine
specific activity are clearly important factors in use of the
isotope dilution procedure. It is fortunate that a radioactive
mercury isotope exists with a sufficiently short half-life of 64.1
hr so that the radiation dose can be kept at a negligible level and
yet provide high enough counting rates to permit accurate
measurement. As an example, in the present case, the random
counting error for the dose measurement at the 99% confidence
level was less than 0.1%. The urine specimens collected from
the patient ranged from 0.078 to 0.176 nCi per 20 ml sample and
were counted with a range of rsd from 11 to 4%. The
efficiency of the counting equipment was established by an NBS
standard reference source of '97Hg with an overall uncertainty
of 1%. The mercury concentration in the urine specimens
ranged from 500 to 1300 ng/ml with method precision [31 (as
determined on 2.2 to 2.8 ng HgIml) of 8.7%. Inasmuch as
patient urine collection periods were 6 hr and the specific
activity as calculated shows no trend for the period 24 to 72 hr
post '97Hg injection, it is possible to calculate the variation from
the average specific activity for the eight 6-hr periods. This
yields a result of 0.753 0.030 (SD) x io nCilng (rsd =
4.1%).
Validation of the two central assumptions. In addition to the
procedural errors considered above, questions may be raised
about the validity of the two central assumptions, that is, (1)
that the kidney takes up to 30% of the injected radioactive dose
and (2) that the specific activity of the kidney is equal to the
specific activity of the urine. The opportunity to test these
assumptions by direct measurement of the pre-dosed human
kidney will necessarily be rare. In default of such evidence
guidance may be sought from animal experiments as performed
for this report and as available in the scientific literature. Table
7 presents animal data on prompt kidney uptake of 203Hg
administered by intravenous or intramuscular injection as Hg
or by inhalation as Hg. Considering the variation exhibited here
and the expectation of individual variations in human uptake,
30% is believed to be an acceptable number. The effect of
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Table 6. Patient's kidney burden of mercury before and after
treatment with DMPS
a The collection was made from 48 to 72 hr post 197Hg injection.
b The values represent decay adjusted to injection time.
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Table 7. Uptake of 203Hg by the kidney after intravenous injection,
inhalation, or intramuscular injection
Animal
species
Number
of
animals
Mode
of
entrya
Sacrifice
time
days
Kidney
% dose Reference
Rats 2 i.v. 1 33 18
Rats 2 iv. 2 40 18
Rats 2 iv. 1 37 19
Rats 2 i.v. 4 20 19
Dogs 3 i.v. 3 to 5 27 This paper
Rats 10 i.v. 3 31 1.1 This paper
Rats (DMPS) 10 i.v. 3 30 1.2 This paper
Rats 2 inh. 1 38 19b
Rats 2 inh. 4 33 b
Rats 8 inh. 3 24.5 1.6 17
Mice 9 inh. 3 23.6 0.4 17
Rats 6 i.m. 1 34 20
Rats 2 i.m. 3 49 20
a 203Hg was in the form of the mercuric salt (Hg) when given by
injection and in the form of vapor of metallic mercury (Hg) when given
by inhalation.b To convert from the authors' units of "% absorbedor injected dose
per gram," a kidney weight of 1.5 g/200 g rat has been assumed.
assigning too high a number is to bring about an estimate of
burden which is proportionately too high. It might be antici-
pated that patients with severe kidney injury might not conform
to the normal pattern.
The assumption that the specific activity of the kidney is
equal to the specific activity of the urine receives support from
the dog data and particularly from the rat data reported in this
paper. The specific activity of the kidney minus the specific
activity of the urine divided by the specific activity of the urine
averages —0.01 for dogs 2, 3, and 4. The rat data permit a more
precise assessment because of the larger number of animals
tested. As reported in the results section, the difference be-
tween the average specific activity of the kidney and of the
urine is less than two times the standard error of the difference
(the exact factor is 1.6 for the control group and 0.9 for the
DMPS group) and therefore is not a significant difference.
This relationship between the two specific activities has been
anticipated on general grounds; Cherian et al [22] in discussions
of the results of inhalation of mercury vapor by volunteer
subjects noted that the specific activity of the plasma was
uniformly higher than that of the urine. They suggested that the
radioactive mercury is exchanged with the kidney pool of
non-radioactive mercury before entering the urine. Cherian et al
[221 dismissed glomerular filtration as a major pathway of
excretion for mercury during the early postexposure period.
Berlin and Gibson [23] arrived at the same conclusion earlier.
Toxicity implications of the estimated kidney burden. Berlin
[24] states that in cases of known poisoning due to mercuric
salts, values between 10 and 70 ppm (jig/g) mercury concentra-
tion in the kidney have been reported using renal biopsy as a
method of determination in human subjects. He adds that "no
other more accessible tissue or medium has been found to
parallel mercury concentration in the kidney."
It may be noted that if the kidney weight of our 52.8 kg
patient is estimated at 275 g, the predicted concentration before
treatment with DMPS is 104 g/g of kidney, which is well into
the toxicity range quoted above. As noted above and as stated
in other parts of this paper, neither blood nor urine mercury
concentrations provide a valid index of kidney burden. Never-
theless, comparison of the ranges of blood concentrations and
urinary concentrations associated with injury as reported in the
literature [2] with the data contained in Figure 4 provides
marginal support to the conclusion that kidney involvement
should be anticipated. A factor which may be important in the
development of injury is the rate and duration of exposure [1,
2]. The effects of this factor and the possibility of an acquired
tolerance require that a note of caution be added to the above
interpretation.
The best data on effect must come from observations and
measurements on the patient. It has already been stated that she
displayed a mild proteinuria, which continues and was present
908 days after the accident. Although details of the in-depth
study of kidney function will be presented in another report, it
can be stated here that the study provides evidence of the injury
predictable from our estimate of kidney mercury burden.
Estimates of mercury burdens in other organs by isotope
dilution method. It may be seen from the specific activities in
Table 2 that as late as 5 days postinjection the exchange
between 203Hg in the plasma and that in the kidney, liver, brain,
and heart is still incomplete. The relatively rapid exchange
between the kidney and urine is unique and diagnostic for that
organ only. The data indicate that exchange between the plasma
and both muscle tissue (as represented by the heart) and brain
is particularly slow. However, it is believed that a complete
mixing would occur given a radioactive isotope of sufficiently
long half-life such as 203Hg. Such an approach would sacrifice
the two advantages of using '97Hg with the short life: (1) the
reduced radiation dose per microcurie injected and (2) the
opportunity to carry out a meaningful second isotope study
after a short chelation therapy treatment. Should the mercury
burden of a particular organ such as the brain be an important
factor in diagnosis or treatment, it would appear preferable to
conduct a study with '97Hg to elicit the kidney burden and to
estimate the brain burden from this benchmark by the use of
appropriate animal data.
Effect of DMPS treatment on mercury content of organs
other than the kidney. Day-by-day analysis of the urinary
excretion of mercury (Hg) before, during, and after treatment of
the patient with DMPS made it possible to estimate an excess
urinary excretion accountable to DMPS. This excess was equal
to 19.8 mg mercury for days 236 to 244 (see Fig. 4). The
estimated kidney loss was 8.8 mg, leaving a total of 11 mg
unaccounted for and presumably representing loss from other
body organs.
The dog data show losses of 58% from the kidney, a question-
ably significant 10% from the liver, 44% from the heart, and
68% from the brain brought about by DMPS treatment. The rat
data show an average loss from the kidney of 26% of the control
value. In contrast no significant loss occurred in the liver or
brain Hg burdens of the treated group. Gabard [25] lists
reductions of inorganic mercury content in DMPS-treated rats
(six animals) as compared to control rats (13 animals) as
follows: kidney, 59%; liver, 21%; skeletal muscle, 27%; brain,
29%; and intestine, 40%. Other data on rats [26] support these
findings. The intraperitoneal daily dose of DMPS administered
by Gabard [25] was approximately three times that used in our
rat experiments and that may account for the difference in the
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results. Our choice of 3 mg DMPS/kg/day i.p. was intended to
approximate the patient dose by mouth of about 6mg/kg/day (30
to 40% absorption from the gut of rats [14]).
Mobilization of mercury from the lung. The form in which
mercury is presented to the blood has important consequences
for its distribution to body tissues. If the exposure is to mercury
vapor, experiments with human volunteers [171 have shown
that amounts averaging 7.1% (6.1 to 8.3) of the absorbed dose
were deposited in the brain. As reported in an unpublished
experiment (Hursh, J. B., personal communication, 1975), a
human volunteer received an intravenous injection of 203Hg and
was studied in the same background facility [161. In this case,
the head position measurement yielded 0.20% of the injected
dose. Animal experiments [18, 201 confirm that the brain
concentration is at least ten times higher after exposure to
mercury via inhalation as compared to the intravenous route. A
variety of data collected in our patient study support the
proposition that mercury was removed from the lung primarily
as the mercuric ion:
Ratio of RBC mercury concentration to plasma concentra-
tion. For humans and animals [17, 20] the ratio ranges from 0.4
to 0.6. After tracer doses of inorganic mercury, Miettinen [27]
found in humans an average HgRBC/HgPI equals 0.4. Thirteen
blood samples drawn from the patient during the period from
days 232 to 241 after exposure yielded an average value for the
above ratio of 0.63 0.03 (sEM) suggesting that the entry of
mercury into the blood occurs primarily as the mercuric ion and
not as vapor.
The fact that the same ratio is uniformly greater than 1 as
determined for the dogs (Fig. 2) is a puzzling result. It may be
that mercury vapor dissolved in the blood plays a greater role in
mobilization of lung-deposited mercury in the case of the dog
rather than for humans. This might occur if the concentration of
catalase in the dog's lungs were low in relation to catalase
concentration in the lung of a human resulting in a lower rate of
in situ oxidation. Deficient blood catalase concentrations in the
dog as compared to humans [5] have been found. In the event
that this explanation is valid, it should be noted that the
distribution of mercury in the dog remains an acceptable model
for distribution in humans with the exception that the deposit in
the dog brain may be slightly higher than that for humans [20].
In respect to measurements qf vapor in the patient's expired
air. As shown in Figure 4, the patient's expired air samples
gathered from days 232 to 245 period yield values from 16 to 38
ng Hg/l2 liters air, with an average value of 27 ng/12 liters. If it
be assumed that the alveolar air comprises 75% of the volume of
the expired air, it may be calculated that the alveolar air
contains 27 ng/9 liters = 3 ng Hg/liter. If the circulating blood is
in equilibrium with the alveolar air in respect to Hg vapor, it
could contain a maximum of 3 x 4.2 = 12.6 ng Hg vapor per
liter of blood, using an Ostwald partition coefficient determined
by one of us (Hursh, J. B., personal communication, 1982).
Consider that, using a circulation time arm to arm equaling 18
sec and a circulating blood volume equaling 4 liters, it can be
estimated that 4 x 12.6 ng Hg could be mobilized from the lung
as vapor every 18 sec or a total of 2.42 x l0 ng = 242 sg Hg
every 24 hr. Experiments on humans have shown that an
inorganic mercury burden leaves the body with an average
half-time of 46 days for male subjects [17, 18, 27] and of 37 days
for female subjects [27]. If the rate of uptake is constant and if
the duration is long in terms of the half-time for loss, it may be
expected that a steady-state will be established in which the rate
of uptake (that is, mobilization from the lung deposit) equals the
mercury loss by excretion. It is plausible that the first condition
is satisfied inasmuch as the pool of lung mercury is large (40 g)
in comparison with the relatively slow rate of mobilization. The
second condition is clearly fulfilled because more than six
half-times have intervened between the accident and initiation
of the study. Therefore, the rate of mobilization from the lung
may be approximated by the rate of loss and set as more than
the average urinary loss of 2100 cg Hg per day ("more than"
because fecal excretion is not accounted for). Therefore, it is
possible to conclude that the calculated maximum rate of
mobilization as vapor equals 242 g Hg per day and must play
a minor role and that for the most part mercury must be
oxidized in the lung and enter the blood as Hg + for distribution
to body tissues. This calculation reinforces the conclusion
arrived at (see above) from the measured RBC to plasma
mercury concentration.
Rate of elimination of mercury deposit from the patient's
lung. It has been estimated that approximately 40 g Hg were
found in the patient's lung. The first DMPS treatment removed
about 20 mg equal to 0.05%. If it is assumed that an additional
amount equal to 2.5 mg/day for 6 months was excreted in the
urine, it can be calculated that about 460 mg (1.2%) were
eliminated by this route. This calculation makes it clear that for
cases of this kind a single chelating treatment provides only
temporary protection of the kidney. The most that can be
expected is that a treatment schedule may be developed which
will maintain the mercury concentration in the kidney at a
subtoxic level.
Summary
The following statements provide a summary of our work:
(1) Experiments on dogs and rats show that isotope dilution
techniques may be used to estimate kidney burdens of mercury.
(2) Animal data, including the present dog data, show that
about 30% of an intravenously injected dose of 203Hg is taken up
by the kidney and that this percentage is independent of the
pre-existing mercury burden of the kidney.
(3) The specific activity of the kidney after an intravenous
dose of 203Hg to dogs or rats is equal to the 48 to 72 hr
postinjection specific activity of the urine.
(4) Dimercaptopropane sulfonate treatment causes a loss of
mercury from the kidney, brain, and probably heart muscle in
dogs. Rats show loss from the kidney but not from the liver or
brain; the difference perhaps is DMPS dose-size dependency.
(5) The isotope dilution method using '97Hg may be applied to
a human subject to predict the kidney burden of mercury before
and after treatment with DMPS.
(6) The amount of increased urinary excretion of mercury by
the patient caused by DMPS requires that losses occur from
body organs or tissues in addition to the estimated kidney loss.
(7) When liquid mercury resident in the lung is the source of
mercury, exposure mobilization from the site acts primarily as
the mercuric ion in human subjects.
(8) Sensitivity of the analytical methods involved would
permit application of the isotope dilution method to estimate
inorganic mercury burdens in the kidneys of selected individu-
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als, suspected of excessive exposure to mercury vapor in the
industrial environment.
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